Physician profile
Firas Askar
NPI 1386272920
$1,853.61
in general payments reported to CMS, 2019-2025
6 companies · $547 in 2025
The $547 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $395 · 2024: $912 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737 · Education: $99.99 · Travel and Lodging: $17.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.62 |
| Education | $99.99 |
| Travel and Lodging | $17.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $469.50 | 2023-2025 | Cimzia, Bimzelx |
| Amgen INC. | $447.56 | 2024-2025 | Tavneos, Otezla, Krystexxa |
| Aurinia Pharma U.S., INC. | $431.73 | 2023-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $267.58 | 2024-2025 | |
| Glaxosmithkline, LLC. | $137.25 | 2023-2024 | Nucala, Benlysta |
| Janssen Biotech, INC. | $99.99 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas Askar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.